Dendreon Corp fka DNDNQ

[ocyanblue]

<The recent abstract from Dr Preylak shows that in the subgroup that received Taxotere after provenge treatment survival was almost doubled over monotherapy. Did all the increase in survival benefit in the provenge arm come from this subgroup.>

Recall that the CD54 data were measured before Provenge was reinfused to patients. The high upreg patients clearly outperformed the low ones. Since chemos & Taxotere treatments were independent decisions without any knowledge of the CD54 data, it would be extremely unlikely that the high upreg group somehow coincided with the Provenge+Taxotere group.